Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xencor, Inc.
Hoffmann-La Roche
University of Michigan Rogel Cancer Center
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Oslo University Hospital
Takeda
Seagen Inc.
HUYABIO International, LLC.
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Transgene
Sotio Biotech Inc.
University of Kentucky
Sanofi
BerGenBio ASA
ImmuneSensor Therapeutics Inc.
Sanofi
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline
Grid Therapeutics
NYU Langone Health
NuCana plc
Formycon AG
Sanofi
Vanderbilt-Ingram Cancer Center
Turnstone Biologics, Corp.
NovoCure Ltd.
Amgen
Seagen Inc.
Achilles Therapeutics UK Limited
Turnstone Biologics, Corp.
Genprex, Inc.
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Tufts Medical Center
MedPacto, Inc.
Inhibrx Biosciences, Inc
Bayer
Novartis
University of Chicago
Wake Forest University Health Sciences
Novartis
ADC Therapeutics S.A.
Portage Biotech
National Institutes of Health Clinical Center (CC)
Ikena Oncology
Augusta University
GlaxoSmithKline